



Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark Ratain <i>et al.</i>	
U.S. Patent Documents <i>See Page 1</i>		Filing Date: January 5, 2004	Group: 1645
		Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 2</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
SB	A9	2002/0061518	5/28/02	Penny and Galvin	435	6	5/05/99
	A10	2003/0077629	4/24/03	Galvin <i>et al.</i>	435	6	7/24/02
	A11	2003/0099960	5/29/03	Ratain <i>et al.</i>	435	6	1/25/02
	A12	2003/0099977	5/29/03	Guida and Kurth	435	6	7/26/02
	A13	2003/0157517	8/21/03	Penny and Galvin	435	6	9/18/02
	A14	2004/0058363	3/25/04	Hasegawa <i>et al.</i>	435	6	6/12/03
	A15	2004/0076968	4/22/04	Acuna <i>et al.</i>	435	6	7/02/01
	A16	2004/0121327	6/24/04	Manns and Strassburg	435	6	1/03/02
	A17	2004/0203034	10/14/04	Ratain <i>et al.</i>	435	6	1/05/04
▼	A18	5,972,614	10/1999	Ruano <i>et al.</i>	436	6	
	A19	6,448,003	9/10/2	Guida and Kurth	435	6	6/08/99
SB	A20	6,586,175	7/01/03	Galvin <i>et al.</i>	435	6	7/20/99

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
SB	B6	JP 2004-073035	3/11/04	Japan			Abstract
	B7	EP 1352970	10/15/03	Europe			English
	B8	WO 01/79230	10/25/01	WIPO			English
	B9	WO 02/053770	7/11/02	WIPO			English
	B10	WO 02/057410	7/25/02	WIPO			English
	B11	WO 02/06523	1/24/02	WIPO			English
▼	B12	WO 2003/013536	2/20/03	WIPO			English
SB	B13	WO 2003/013537	2/20/03	WIPO			English

25507126.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006
--------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark Ratain <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 2</i>	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
SB	B14	WO 2004/016814	2/26/04	WIPO			Abstract
SB	B15	WO 97/32042	9/04/97	WIPO			English
SB	B16	WO 99/57322	11/11/99	WIPO			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C218	Ando <i>et al.</i> , "UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan," <i>Annals of Oncology</i> , 9:845-847, 1998.
SB	C219	Beutler <i>et al.</i> , "Racial variability in the UDP-glucuronosyltransferase 1(UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism," <i>Proc. Natl. Acad. Sci., USA</i> , 95:8170-8174, 1998.
SB	C220	Clarke <i>et al.</i> , "Genetic defects of the UDP-glucuronosyltransferase-1 (UGT1) gene that cause familial non-hemolytic unconjugated hyperbilirubinemias," <i>Clinica Chimica Acta</i> , 266:63-74, 1997.
SB	C221	De Morais <i>et al.</i> , "Decreased glucuronidation and increased bioactivation of Acetaminophen in Gilbert's syndrome," <i>Gastroenterology</i> , 102:577-586, 1992.

25507126.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006
--------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

ARCD:389US

10/751,606

Applicant

Mark J. Ratain *et al.*

Filing Date:

January 5, 2004

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
SB	A1	5,786,344	7/28/98	Ratain <i>et al.</i>	514	100	4/17/95
	A2	6,066,645	5/23/00	Hausheer <i>et al.</i>	514	283	1/6/99
	A3	6,287,834	9/11/01	Belanger <i>et al.</i>	435	193	2/08/99
	A4	6,319,678	11/20/01	Trubetskoy and Shaw	435	15	6/25/99
	A5	6,395,481	5/28/02	Di Rienzo <i>et al.</i>	435	6	1/16/99
	A6	6,407,117	6/18/02	Bouscarel <i>et al.</i>	514	283	3/23/00
	A7	6,472,157	10/29/02	De Rienzo and Ratain	435	6	2/01/02
	A8	6,479,236	11/12/02	Penny and Galvin	435	6	5/05/99

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
SB	B1	EP 0919244	6/2/99	Europe			Abstract
SB	B2	WO 00/06776	2/10/00	PCT			
SB	B3	WO 94/22846	10/94	PCT			
SB	B4	WO 95/08986	4/6/95	PCT			
SB	B5	WO 96/01127	1/18/96	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C1	Abraham <i>et al.</i> , "Non-glucocorticoid steroid analogues (21-aminosteroids) sensitize multidrug resistant cells to vinblastine," <i>Cancer Chemother. Pharmacol.</i> , 32(2):116-122, 1993.
SB	C2	Akiyama <i>et al.</i> , "Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of p-glycoprotein by a vinblastine analog," <i>Mol. Pharmacol.</i> , 33(2):144-147, 1988.

25389367.1

EXAMINER: /Sarae Bausch/

DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark J. Ratain <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C3	Ando <i>et al.</i> , "Polymorphisms of UDP-glycuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis," <i>Cancer Res.</i> , 60(24):6921-6926, 2000.
	C4	Ansher <i>et al.</i> , "Chemoprotective effects of two dithiolthiones and of butylhydroxyanisole against carbon tetrachloride and acetaminophen toxicity," <i>Hepatology</i> , 3(6):932-935, 1983.
	C5	Araki <i>et al.</i> , "Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and blood plasma of athymic mice following intraperitoneal administration of CPT-11," <i>Jpn J. Cancer Res.</i> , 84:697-702, 1993.
	C6	Ariyoshi <i>et al.</i> , "Mouse-human chimeric antibody MH171 against the multidrug transporter P-glycoprotein," <i>Jpn. J. Cancer Res.</i> , 83(5):515-521, 1992.
	C7	Atsumi <i>et al.</i> , "Identification of the Metabolites of Irinotecan, a New Derivative of Camptothecin, in Rat Bile and its Biliary Excretion," <i>Xenobiotica</i> , 21(9):1159-1169, 1991.
	C8	Barbier <i>et al.</i> , "3'-azido-3'-deoxythymidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 3B7 (UGT2B7)," <i>Drug Metab. Dispos.</i> , 28:497-502, 2000.
	C9	Barker <i>et al.</i> , "Determination of plasma concentrations of epirubicin and its metabolites by high-performance liquid chromatography during a 96-h infusion in cancer chemotherapy," <i>J Chromatogr B Biomed Appl.</i> , 681:323-329, 1996.
	C10	Bear, "Drugs transported by-P-glycoprotein inhibit a 40pS outwardly rectifying chloride channel," <i>Biochem. Biophys. Res. Commun.</i> , 200(1):513-521, 1994.
	C11	Bell <i>et al.</i> , "Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and rapamycin," <i>Biochem. Pharmacol.</i> , 48(3):495-503, 1994.
	C12	Bertrand <i>et al.</i> , "Sequential Administration of Camptothecin and Etoposide Circumvents the Antagonistic Cytotoxicity of Simultaneous Drug Administration in Slowly Growing Human Colon Carcinoma HT-29 Cells," <i>Eur. J. Cancer</i> , 28A(4-5):743-748, 1992.
	C13	Beutler <i>et al.</i> , "Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism," <i>PNAS USA</i> , 95(14):8170-8174, 1998.
SB	C14	Bhasker <i>et al.</i> , "Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance," <i>Pharmacogenetics</i> , 10(8):679-685, 2000.

25389367.1

EXAMINER: /Sarae Bausch/

DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark J. Ratain <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C15	Bible and Kaufmann, "Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration," <i>Cancer Res.</i> , 57:3375-3380, 1997.
	C16	Bible and Kaufmann, "Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells," <i>Cancer Res.</i> , 56:4856-4861, 1996.
	C17	Bock <i>et al.</i> , In: <i>Conjugation reactions in biotransformation</i> , Elsevier, North Holland Biomedical Press, p. 357-364, 1978.
	C18	Boesch and Loor, "Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents," <i>Anticancer Drugs</i> , 5(2):229-238, 1994.
	C19	Boesch <i>et al.</i> , "Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative," <i>Exp. Cell. Res.</i> , 196(1):26-32, 1991.
	C20	Boiteux-Antoine <i>et al.</i> , "Comparative induction of drug-metabolizing enzymes by hypolipidaemic compounds," <i>Gen-Pharmacol.</i> , 20(4):407-412, 1989.
	C21	Bosma <i>et al.</i> , "Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar Syndrome, Type I," <i>Hepatology</i> , 15:941-947, 1992.
	C22	Bosma <i>et al.</i> , "The genetic basis of the reduced expression of bilirubin UDP-Glucuronosyltransferase 1 in Gilbert's Syndrome," <i>N. Eng. J. Med.</i> , 333:1171-1175, 1995.
	C23	Burchell and Coughtrie, "UDP-glucuronosyltransferases," <i>Pharmac. Ther.</i> , 43:261-289, 1989.
	C24	Burchell <i>et al.</i> , "The UDP Glucuronosyltransferase gene suprefamily: suggested nomenclature based on evolutionary divergence," <i>DNA cell biol.</i> , 10:487-494, 1991.
	C25	Burger <i>et al.</i> , "Pharmacokinetic interaction between rifampin and zidovudine," <i>Antimicrobial Agents and Chemotherapy</i> , 37(7):1426-1431, 1993.
	C26	Campain <i>et al.</i> , "Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II," <i>J. Cell Physiol.</i> , 155(2):414-425, 1993.
SB	C27	Carlson <i>et al.</i> , "Flavopiridol induces G ¹ arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells," <i>Cancer Res.</i> , 56:2973-2978, 1996.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006
--------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark J. Ratain <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C28	Carrier <i>et al.</i> , "Isolation and characterization of the human UGT2B7 gene," <i>Biochem and Biophys. Res. Commun.</i> , 272:616-621, 2000.
	C29	Cascorbi <i>et al.</i> , "Frequency of single nucleotide polymorphisms in the p-glycoprotein drug transporter MDR1 gene in white subjects," <i>Clinc. Pharmacol Ther.</i> , 69:169-174, 2001.
	C30	Charuk <i>et al.</i> , "Interaction of Rat Kidney P-Glycoprotein with a Urinary Component and Various Drugs Including Cyclosporin A," <i>Am. J. Physiol.</i> , 266:F66-F75, 1994.
	C31	Chen <i>et al.</i> , "Fluorescence polarization in homogeneous nucleic acid analysis," <i>Genome Res.</i> , 9:492-498, 1999.
	C32	Chem <i>et al.</i> , "Calcium phosphate-mediated gene transfer: A highly efficient transfection system for stably transforming cells with plasmid DNA," <i>Biotechniques</i> , 6:632-638, 1988.
	C33	Cheng <i>et al.</i> , "Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7," <i>Toxicological Sciences</i> , 45:52-57, 1998.
	C34	Chien <i>et al.</i> , "In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer," <i>Cancer Chemother Pharmacol.</i> , 44:81-87, 1999.
	C35	Chin <i>et al.</i> , "Reduced mRNA levels for multidrug-resistance genes in cAMP-dependent protein kinase mutant cell lines," <i>J. Cell Physiol.</i> , 152(1):87-94, 1992.
	C36	Clarke and Burchell, "The Uridine Diphosphate glucuronosyltransferase multigene family: function and regulation," <i>Handbook of experimental pharmacology</i> , 112:3-43, 1994.
	C37	Coffman <i>et al.</i> , "Cloning and stable expression of a cDNA encoding a rat liver UDP-Glucuronosyltransferase (UDP-Glucuronosyltransferase 1.1) that catalyzes the glucuronidation of opioids and bilirubin," <i>Mol. Pharmacol.</i> , 47:1101-1105, 1995.
	C38	Coffman <i>et al.</i> , "Human UGT2B7 catalyzes morphine glucuronidation," <i>Drug Metab Dispos.</i> , 25:1-4, 1997.
	C39	Coffman <i>et al.</i> , "The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268)," <i>Drug Metab Dispos.</i> , 26:73-77, 1998.
↓	C40	Cordon-Cardo <i>et al.</i> , "Expression of the multidrug resistant gene product (P-glycoprotein) in human normal and tumor tissues," <i>J. Histochem. Cytochem.</i> , 38:1277-1287, 1990.
SB	C41	Czech <i>et al.</i> , "Antitumoral activity of flavone L86-8275," <i>Int J Oncol.</i> , 6:31-66, 1995.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006
--------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark J. Ratain <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C42	Davies and Schnell, "Oltipraz-induced amelioration of acetaminophen hepatotoxicity in hamsters," <i>Toxicology and Applied Pharmacology</i> , 109:29-40, 1991.
	C43	de Forni <i>et al.</i> , "Phase I and pharmacokinetic study of the camptothecin derivative irinotecan administered on a weekly schedule in cancer patients," <i>Cancer Res.</i> , 54:4347-4354, 1994.
	C44	De Lannoy <i>et al.</i> , "Cyclosporin and Quinidine Inhibition of Renal Digoxin Excretion: Evidence for Luminal Secretion of Digoxin," <i>Am. J. Physiol.</i> , 263:F613-F622, 1992.
	C45	De Morais <i>et al.</i> , "Biotransformation and Toxicity of Acetaminophen in Congenic RHA Rats with or without a Hereditary Deficiency in Bilirubin UDP-Glucuronosyltransferase," <i>Toxicology and Applied Pharmacology</i> , 117:81-87, 1992.
	C46	Decleves <i>et al.</i> , "A new polymorphism (N21D) in the exon 2 of the human MDR1 gene encoding the P-glycoprotein," <i>Human Mutation</i> , 15: 486, 2000.
	C47	Dhainaut <i>et al.</i> , "New Triazine Derivatives as Potent Modulators of Multidrug Resistance," <i>J. Med. Chem.</i> , 35:2481-2496, 1992.
	C48	Di Carlo <i>et al.</i> , "Flavonoids: old and new aspects of a class of natural therapeutic drugs," <i>Life Sci.</i> , 65:337-353, 1999.
	C49	Di Rienzo <i>et al.</i> , "Two new alleles in the promoter of the bilirubin UDP-glucuronosyl transferase 1 (UGT1A1) gene", <i>American Society for Clinical Pharmacology and Therapeutics</i> , Ninety Ninth Annual Meeting, New Orleans, Abstract OII-B-3, page 207, 1998.
	C50	Diasio <i>et al.</i> , "Clinical pharmacology of 5-fluorouracil," <i>Clin Pharmacokinet</i> , 16:215-237, 1989.
	C51	Dobbs and Twelves, "What is the effect of adjusting epirubicin doses for body surface area?" <i>British Journal of Cancer</i> , 78(5):662-666, 1998.
	C52	Doige <i>et al.</i> , "ATPase activity of partially purified P-glycoprotein from multidrug-resistant chinese hamster ovary cells," <i>Biochim. Biophys. Acta.</i> , 1109(2):149-160, 1992.
	C53	Drees <i>et al.</i> , "Flavopiridol (86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells," <i>Clin Cancer Res.</i> , 3:273-279, 1997.
SB	C54	Egner <i>et al.</i> , "Regulation of Phase 2 Enzyme Induction by Oltipraz and other Dithiolethiones," <i>Carcinogenesis</i> , 15(2):177-181, 1994.

25389367.1

EXAMINER: /Sarae Bausch/

DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark J. Ratain <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C55	Ewesuedo and Ratain, "Topoisomerase I inhibitors," <i>Oncologist</i> , 2(6):359-364, 1997.
	C56	Evans and Relling, "Automated high-performance liquid chromatographic assay for the determination of 7-ethoxycoumarin and umbelliferone," <i>J. Chromatogr.</i> , 578:141-145, 1992.
	C57	Ford <i>et al.</i> , "Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines," <i>Cancer Res.</i> , 50(6):1748-1756, 1990.
	C58	Fournel <i>et al.</i> , "Structure-dependent induction of bilirubin glucuronidation and lauric acid 12-hydroxylation by arylcarboxylic acids chemically related to clofibrate," <i>Biochimica et Biophysica Acta</i> , 842:202-213, 1985.
	C59	Foxwell <i>et al.</i> , "Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein," <i>Mol. Pharmacol.</i> , 36:543-546, 1989.
	C60	Friche <i>et. al.</i> , "In vitro circumvention of anthracycline-resistance in ehrlich ascites tumour by anthracycline analogues" <i>Biochem. Pharmacol.</i> , 39:1721-1726, 1990.
	C61	GenBank Accession Number AF297093.
	C62	GenBank Accession Number NM_001074.
	C63	Gestl <i>et al.</i> , "Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in Situ breast cancers," <i>American Journal of Pathology</i> , 160(4):1467-1479, 2002.
	C64	Gram <i>et al.</i> , "Clinical relevance of genetic polymorphisms in drug oxidation," <i>Clinical Relevance of Genetic Polymorphisms in Drug Oxidation</i> , 1992.
	C65	Green <i>et al.</i> , "Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides," <i>Drug Metab. Dispos.</i> , 23:299-302, 1995.
	C66	Gruol <i>et al.</i> , "Reversal of multidrug resistance by RU 486 ¹ ," <i>Cancer Res.</i> , 54(12):3088-3091, 1994.
↓	C67	Guillamette <i>et al.</i> , "Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans," <i>Cancer Res.</i> , 60:950-956, 2000.
SB	C68	Gunn, "Hereditary Acholuric Jaundice," <i>J. Hered.</i> , 29:137-139, 1938.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006
--------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark J. Ratain <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C69	Gupta <i>et al.</i> , "Metabolic Fate of Irinotecan in humans: Correlation of Glucuronidation with Diarrhea," <i>Cancer Res.</i> , 54:3723-3725, 1994.
	C70	Gupta <i>et al.</i> , "Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor Irinotecan in cancer patients," <i>J. Clin. Oncol.</i> , 15:1502-1510, 1997.
	C71	Gupta <i>et al.</i> , "Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital, <i>Cancer Chemother. Pharmacol.</i> , 39(5):440-444, 1997.
	C72	Gupta <i>et al.</i> , "Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A., <i>Cancer Res.</i> , 56(6):1309-1314, 1996.
	C73	Gupta <i>et al.</i> , "Role of carboxyl esterase in the metabolism of CPT-11, a camptothecin analog, in humans" <i>Pharm. Res.</i> , 11:S450, 1994.
	C74	Gutmann <i>et al.</i> , "Modulation of multidrug resistance protein expression in porcine brain capillary endothelial cells in vitro," <i>Drug Metab Dispos.</i> 27:937-941, 1999.
	C75	Hait <i>et al.</i> , "Terferadine (seldane®): a new drug for restoring sensitivity to multidrug resistant cancer cells" <i>Biochem. Pharmacol.</i> , 45(2):401-406, 1993.
	C76	Hamada <i>et al.</i> , "Mouse-human chimeric antibody against the multidrug transporter P-glycoprotein" <i>Cancer Res.</i> , 50(11):3167-3171, 1990.
	C77	Harding <i>et al.</i> , "Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells," <i>PNAS, USA</i> , 85:8381-8385, 1988.
	C78	Hecht <i>et al.</i> , "4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and its glucuronide, metabolites of a tobacco-specific lung carcinogen, in the urine of black and white smokers," <i>Proceedings of the American Association for Cancer Research</i> , 35:1702, 1994.
	C79	Hendricks <i>et al.</i> , "Effect of P-Glycoprotein Expression on the Accumulation and Cytotoxicity of Topotecan (SK&F 104864), a New Camptothecin Analogue," <i>Cancer Research</i> , 52:2268-2278, April 1992.
	C80	Hjelle, "Hepatic UDP-Glucuronic Acid Regulation during Acetaminophen Biotransformation in Rats," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 237(3):750-756, 1986.
SB	C81	Hoffmeyer <i>et al.</i> , "Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations an dcorrelation of one allele with p-glycoprotein expression and activity in vivo," <i>PNAS</i> , 28:97(7):3473-3478, 2000.

25389367.1

EXAMINER:	/Sarae Bausch/	DATE CONSIDERED:
-----------	----------------	------------------

07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark J. Ratain <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C82	Holthe <i>et al.</i> , "Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1a1*28 polymorphisms in cancer patients on chronic morphine therapy," <i>European Journal of Clinical Pharmacology</i> , 58: 353-356, 2002.
	C83	Hooijberg <i>et al.</i> , "Potent interaction of flavopiridol with MRP1," <i>British J. of Cancer</i> , 81:269-276, 1999.
	C84	Hsu <i>et al.</i> , "Universal SNP genotyping assay with fluorescence polarization detection," <i>BioTechniques</i> , 31:560-570, 2001.
	C85	Hunter <i>et al.</i> , "Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial caco-2 cell layers" <i>Pharm. Res.</i> , 10(5):743-749, 1993.
	C86	Ichikawa-Haraguchi <i>et al.</i> , "Progesterone and its metabolites: the potent inhibitors of the transporting activity of P-glycoprotein in the adrenal gland" <i>Biochim. Biophys. Acta</i> , 1158(3):201-208, 1993.
	C87	Innocenti <i>et al.</i> , "Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan," <i>Drug Metab. Dispos.</i> , 29(4 pt 2):596-600, 2001.
	C88	Innocenti <i>et al.</i> , "Pharmacogenetics: a tool for individualizing antineoplastic therapy," <i>Clin. Pharmacokinet.</i> , 39(5):315-325, 2000.
	C89	Innocenti <i>et al.</i> , "Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyl transferase 2B7," <i>Drug Metab. Dispos.</i> , 29(5):686-692, 2001.
	C90	Innocenti <i>et al.</i> , "Epirubicin is glucuronidated by UGT2B7," <i>Clinical Pharmacology and Therapeutics</i> , 67(2):100, Abstract PI-44, 2000.
	C91	Innocenti <i>et al.</i> , "Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea," <i>Clinical Cancer Research</i> , 6:3400-3405, 2000.
	C92	Innocenti <i>et al.</i> , "Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups," <i>Pharmacogenetics J.</i> , 12(9):725-733, 2002.
	C93	Inoue <i>et al.</i> , "Cellular detoxification of tripeptidyl aldehydes by an aldo-keto reductase" <i>J. Biol. Chem.</i> , 268(8):5894-5898, 1993.
	C94	Ishii <i>et al.</i> , "Octamer transcription factor-1 enhances hepatic nuclear factor-1 α -mediated activation of the human UDP glucuronosyltransferase 2B7 promoter," <i>Molecular Pharmacology</i> , 57:940-947, 2000.

25389367.1

EXAMINER:	/Sarae Bausch/	DATE CONSIDERED:	07/24/2006
-----------	----------------	------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark J. Ratain <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1645
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C95	Ito <i>et al.</i> , "Polymorphism of the abc transporter genes mdr1, mrp1 and mrp2/cmoat, in healthy japanese subjects," <i>Pharmacogenetics</i> , 11:175-184, 2001.
	C96	Iyer and Ratain, "Pharmacogenetics and cancer chemotherapy," <i>Eur J Cancer</i> , 34:1493-1499, 1998.
	C97	Iyer <i>et al.</i> , "Genetic basis for the glucuronidation of SN-38: Role of UGT*1 isoform," <i>Clinical Pharmacology and Therapeutics</i> , 61:Abstract, 1997.
	C98	Iyer <i>et al.</i> , "Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes," <i>J. Clin. Invest.</i> , 101(4):847-854, 1998.
	C99	Iyer <i>et al.</i> , "Glucuronidation of TAS-103 by uridine diphosphate glucuronosyltransferase (UGT) isoforms 1A1 and 2: possible implication of TAS-103 toxicity in Gilbert's syndrome," <i>Ann Oncol</i> 9(Supplement 2):61, abstract #230, 1998.
	C100	Iyer <i>et al.</i> , "UGT isoform 1.1 (UGT*1.1) glucuronidates SN-38, the active metabolite of irinotecan," <i>Program Proceedings of the American Society of Clinical Oncology</i> , 16:Abstract, 1997.
	C101	Iyer <i>et al.</i> , "Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism," <i>Clin. Pharmacol. Ther.</i> , 65(5):576-582, 1999.
	C102	Iyer, "Inherited variations in drug-metabolizing enzymes: significance in clinical oncology," <i>Mol Diagnosis</i> , 4:327-333, 1999.
	C103	Iyer <i>et al.</i> , "UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity," <i>Pharmacogenetics J.</i> , 2(1):43-47, 2002.
	C104	Iyer <i>et al.</i> , "Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice," <i>Cancer Chemother. Pharmacol.</i> , 49(4):336-341, 2002.
	C105	Jager <i>et al.</i> , "Metabolism of the anticancer drug vlavopiridol, a new inhibitor of cyclin dependent kinases in rat liver," <i>Life Sci.</i> , 62:1861-1873, 1998.
SB	C106	Jin <i>et al.</i> , "cDNA cloning and expression of two new members of the human glucuronosyltransferase 2B subfamily," <i>Biochem. Biophys. Res. Comm.</i> , 194(1):496-503, 1993.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006
--------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark J. Ratain <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C107	Jin <i>et al.</i> , "Complementary deoxyribonucleic acid cloning and expression of human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs," <i>J. Pharm. Experim. Therap.</i> , 264(1):475-479, 1993.
	C108	Kamimoto <i>et al.</i> , "The function of GP-170, the multidrug resistant gene product, in rat liver canalicular membrane vesicles," <i>J. Biol. Chem.</i> , 264:11693-11698, 1989.
	C109	Kamiwatari <i>et al.</i> , "Correlation between reversing of multidrug resistance and inhibiting of [³ H]azidopine photolabeling of P-glycoprotein by newly synthesized dihydropyridine analogues in a human cell line," <i>Cancer Res.</i> , 49(12):3190-3195, 1989.
	C110	Kaneda <i>et al.</i> , "Metabolism and Pharmacokinetics of the camptothecin analogue CPT-11 in the mouse," <i>Cancer Res.</i> , 50:1715-1720, 1990.
	C111	Kano <i>et al.</i> , "Effects of CPT-11 in Combination with Other Anti-Cancer Agents in Culture," <i>Int. J. Cancer</i> , 50(4):604-610, 1992.
	C112	Karato <i>et al.</i> , "Phase I Study of CPT-11 and Etoposide in Patients with Refractory Solid Tumors," <i>J. Clin. Oncol.</i> , 11(10):2030-2035, 1993.
	C113	Kaufmann, "Antagonism Between Camptothecin and Topoisomerase II-Directed Chemotherapeutic Agents in a Human Leukemia Cell Line," <i>Cancer Res.</i> , 51(4):1129-1136, 1991.
	C114	Kaur <i>et al.</i> , "Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275," <i>J Natl Cancer Inst.</i> , 84:1736-1740, 1992.
	C115	King <i>et al.</i> , "The Glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-Glucuronosyltransferase 1.1," <i>Arch. Biochem. Biophys.</i> , 332:92-100, 1996.
	C116	Kiue <i>et al.</i> , "Activities of newly synthesized dihydropyridines in overcoming of vincristine resistance, calcium antagonism, and inhibition of photoaffinity labeling of P-glycoprotein in rodents," <i>Cancer Res.</i> , 50(2):310-317, 1990.
↓	C117	Klein <i>et al.</i> , "An inventory of the human ABC proteins," <i>Bioch Biophys Acta</i> , 1461:237-262, 1999.
SB	C118	Klein <i>et al.</i> , "Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide," <i>Clin. Pharmacol. Ther.</i> , 72(6):638-647, 2002.

25389367.1

EXAMINER: <i>/Sarae Bausch/</i>	DATE CONSIDERED: 07/24/2006
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark J. Ratain <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1645
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C119	Kusuhara <i>et al.</i> , "Reduced folate derivatives are endogenous substrates for cmoat in rats," <i>Am J Physiol.</i> , 275(4 Pt 1):G789-G796, 1998.
	C120	Lampe <i>et al.</i> , "Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y)," <i>Cancer Epidemiology, Biomarkers and Prevention, american Association for Cancer Research</i> , 9:329-333, 2000.
	C121	Lennard <i>et al.</i> , "Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism," <i>Clin. Pharmacol. Ther.</i> , 46:149-154, 1989.
	C122	Lennard, "The clinical pharmacology of 6-mercaptopurine," <i>Eur J Clin Pharmacol</i> , 43:329-339, 1992.
	C123	Levesque <i>et al.</i> , "Characterization and substrate specificity of UGT2B4 (E ⁴⁵⁸ : a udp-glucuronosyltransferase encoded by a polymorphic gene," <i>Pharmacogenetics</i> , 9:207-216, 1999.
	C124	Levesque <i>et al.</i> , "Isolation and characterization of UGT2B15(Y ⁸⁵): a UDP-glucuronosyltransferase encoded by a polymorphic gene," <i>Pharmacogenetics</i> , 7:317-325, 1997.
	C125	Lokeic <i>et al.</i> , "Pharmacokinetics of irinotecan and its metabolites in human blood, bile and urine," <i>Cancer Chemother. Pharmacol.</i> , 36:79-82, 1995.
	C126	Lomri <i>et al.</i> , "Hepatocellular transport: role of atp-binding cassette proteins," <i>Semin. Liv. Dis.</i> , 16: 201-210, 1996.
	C127	Losiewicz <i>et al.</i> , "Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275," <i>Biochem Biophys Res Commun</i> , 201:589-595, 1994.
	C128	Lubet <i>et al.</i> , "A Pleiotropic Response to Phenobarbital-Type Enzyme Inducers in the F344/NCr RAT," <i>Chemical Pharmacology</i> , 43(5):1067-1078, 1992.
	C129	Lum <i>et al.</i> , "Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance," <i>J. Clin. Oncol.</i> , 10:1635-1642, 1992.
	C130	Mackenzie <i>et al.</i> , "Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance," <i>Clin. Chem. Lab. Med.</i> , 38(9):889-892, 2000.
SB	C131	Mackenzie <i>et al.</i> , "The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence," <i>Pharmacogenetics</i> , 7:255-269, 1997.

25389367.1

EXAMINER: <i>/Sarae Bausch/</i>	DATE CONSIDERED: 07/24/2006
------------------------------------	--------------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark J. Ratain <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C132	Magdalou <i>et al.</i> , "Peroxisome proliferators as inducers and substrates of UDP-glucuronosyltransferases," <i>Biol. Cell.</i> , 77(1):13-16, 1993.
	C133	Makhija <i>et al.</i> , "Cytotoxicity of flavopiridol in ovarian cancer cells alone and in combination with CDDP," <i>Gynecologic Oncology</i> , 68(1):83, Abstract #43, 1998.
	C134	Mani and Ratain, "Promising new agents in oncologic treatment," <i>Curr. Opin. Oncol.</i> , 8(6):525-534, 1996.
	C135	Manning and Franklin, "Induction of rat UDP-glucuronosyltransferase and glutathione S-transferase activities by L-buthionine-S,R-sulfoximine without induction of cytochrome P-450," <i>Toxicology</i> , 65:149-159, 1990.
	C136	Mazzanti <i>et al.</i> , "Bile acid inhibition of P-glycoprotein-mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles," <i>Hepatology</i> , 20(1 Pt 1):170-176, 1994.
	C137	McKinney and Hosford, "ATP-stimulated tetraethylammonium transport by rabbit renal brush border membrane vesicles," <i>J. Biol. Chem.</i> , 268(10):6886-6895, 1993.
	C138	Mechetner and Roninson, "Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody," <i>Proc. Natl. Acad. Sci. USA</i> , 89(13):5824-5828, 1992.
	C139	Meech and Mackenzie, "Determinants of UDP-glucuronosyltransferase membrane association and residency in the endoplasmic reticulum," <i>Arch Biochem Biophys.</i> , 356:77-85, 1998.
	C140	Michelson and Slate, "A Mathematical Model for the Inhibition of the Multidrug Resistance-Associated P-Glycoprotein Pump," <i>Bulletin of Mathematical Biology</i> , 56(2):207-223, 1994.
	C141	Mick <i>et al.</i> , "Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity," <i>J. Clin. Oncol.</i> , 14(7):2012-2019, 1996.
	C142	Miki and Kotake, "Advantages in combination chemotherapy using the camptothecin analogue CPT-11 and cisplatin analogues for human testicular cancer xenografts," <i>Hinyokika Kiyo</i> , 39(12):1221-1225, 1993.
	C143	Miller <i>et al.</i> , "P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil," <i>J. Clin. Oncol.</i> , 9(1):17-24, 1991.
SB	C144	Miners and Mackenzie, "Drug glucuronidation in humans," <i>Pharmacol Ther.</i> , 51:347-369, 1991.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006
--------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark J. Ratain <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1645
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C145	Miyamoto <i>et al.</i> , "Multidrug resistance in yoshida rat ascites hepatoma cell lines" <i>Anticancer Res.</i> , 12(3):649-653, 1992.
	C146	Miyamoto <i>et al.</i> , "Inhibition of multidrug resistance by a new staurosporine derivative, NA-382, in vitro and in vivo," <i>Cancer Res.</i> , 53(7):1555-1559, 1993.
	C147	Miyamoto <i>et al.</i> , "Reversal of vinblastine resistance by a new staurosporine derivative, NA-382, in P388/ADR cells" <i>Cancer Lett.</i> , 64(2):177-183, 1992a.
	C148	Monaghan <i>et al.</i> , "Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome," <i>Lancet</i> , 347:578-581, 1996.
	C149	Morris <i>et al.</i> , "Interaction of forskolin with the P-glycoprotein multidrug transporter," <i>Biochemistry</i> , 30(34):8371-8379, 1991.
	C150	Muller <i>et al.</i> , "ATP-dependent transport of amphiphilic cations across the hepatocyte canalicular membrane mediated by mdr1 P-glycoprotein," <i>FEBS Lett.</i> , 343(2):168-172, 1994.
	C151	Murthi <i>et al.</i> , "Structure-activity relationship studies of flavopiridol analogues," <i>Bioorganic Med Chem Ltrs</i> , 10:1037-1041, 2000.
	C152	Nakajima <i>et al.</i> , "Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes," <i>Drug Metabolism and Disposition</i> , 30(11):1250-1256, 2002.
	C153	Narita <i>et al.</i> , "Inhibition of Beta-Glucuronidase by Natural Glucuronides of <u>Kampo</u> Medicines Using Glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a Substrate," <i>Xenobiotica</i> , 23(1):5-10, 1993.
	C154	Nebert, "Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?" <i>Clin Gen</i> , 56:247-258, 1999.
	C155	Negoro <i>et al.</i> , "Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer," <i>Journal of the National Cancer Institute</i> , 83(16):1164-1168, 1991.
SB	C156	Niwa <i>et al.</i> , "Effect of a dihydropyridine analogue, 2-[benzyl(phenyl)amino]ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1-(2-morpholino-ethyl)-4-(3-nitrophenyl)-3-(pyridinecarboxylate on reversing in vivo resistance of tumor cells to adriamycin," <i>Cancer Res.</i> , 52(13):3655-3660, 1992.

25389367.1

EXAMINER: <i>/Sarah Bausch/</i>	DATE CONSIDERED: 07/24/2006
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark J. Ratain <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation	
SB	C157	Ohe <i>et al.</i> , "Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion," <i>Journal of the National Cancer Institute</i> , 84(12):972-974, 1992.	
	C158	Ohi <i>et al.</i> , "Intravesical instillation of adriamycin in the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study," <i>Cancer Chemother Pharmacol</i> , 30:S50-S54, 1992.	
	C159	Okamura <i>et al.</i> , "Digoxin-cyclosporin A interaction: Modulation of the multidrug transporter P-glycoprotein in the kidney," <i>J. Pharmacol. Exp. Therap.</i> , 266:1614-1619, 1993.	
	C160	Owens and Ritter, "Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity and regulation," <i>Progress in Nucleic Acid Research and Molecular Biology</i> , 51:305-338, 1995.	
	C161	Perdu and Germain, "Identification of novel polymorphisms in the pm5 and mrp1(abcc1) genes at locus 16p13.1 and exclusion of both genes as responsible for pseudoxanthoma elasticum," <i>Human Mutation</i> , 17:74-75, 2001.	
	C162	Perez <i>et al.</i> , "Mechanisms and Modulation of Resistance to Chemotherapy in Ovarian Cancer," <i>Cancer Supplement</i> , 71(4):1571-1580, February 1993.	
	C163	Pourtier-Manzanedo <i>et al.</i> , "Expression of P-glycoprotein on normal lymphocytes: enhancement of the doxorubicin-sensitivity of concanavalin a -responding mouse spleen cells by P-glycoprotein blockers," <i>Oncol. Res.</i> , 4:473-480, 1992.	
	C164	Prochaska and Fernandes, "Elevation of serum Phase II enzymes by anticarcinogenic enzyme inducers: markers for a chemoprotected state?," <i>Carcinogenesis</i> , 14(12):2441-2445, 1993.	
	C165	Purba <i>et al.</i> , "The metabolism of 17 α-ethinylestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites," <i>Br. J. Clin. Pharmacol.</i> , 23:447-453, 1987.	
	C166	Radominska-Pandya <i>et al.</i> , "Human UDP-glucuronosyltransferase 2B7," <i>Curr. Drug. Metab.</i> , 2:283-298, 2001.	
SB	C167	Rajaonarison <i>et. al.</i> , "In vitro glucuronidation of 3'-azido-3' -deoxythymidine by human liver," <i>Drug Metab. Disp.</i> , 19:809-815, 1993.	
SB	C168	Ramirez <i>et al.</i> , "In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes," <i>Pharm. Res.</i> , 19(5):588-594, 2002.	

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED/24/2006
--------------------------	-------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark J. Ratain <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1645
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C169	Ramírez <i>et al.</i> , "In vitro glucuronidation of flavopridol (NSC649890) (flavo) by human liver microsomes," <i>Clin Pharmacol Ther</i> , 63:149, Abstract # PI-50, 1998.
	C170	Ratain <i>et al.</i> , "Paradoxical relationship between acetylator phenotype and amonafide toxicity," <i>Clin. Pharmacol. Ther.</i> , 50:573-579, 1991.
	C171	Ratain, "Irinotecan dosing: does the CPT in CPT-11 stand for "Can't predict toxicity?"" <i>J. Clin. Oncol.</i> , 20(1):7-8, 2002.
	C172	Ratain, "Insights into the pharmacokinetics and pharmacodynamics of irinotecan," <i>Clin. Cancer Res.</i> , 6:3393-3394, 2000.
	C173	Ritter <i>et al.</i> , "A novel complex locus UGT1 encodes human bilirubin, phenol and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini," <i>J. Biol. Chem.</i> , 267:3257-3261, 1992.
	C174	Ritter <i>et al.</i> , "Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells," <i>J. Biol. Chem.</i> , 226:1043-1047, 1991.
	C175	Robert, "Clinical pharmacokinetics of epirubicin," <i>Clin. Pharmacokinet</i> , 26:428-438, 1994
	C176	Robey <i>et al.</i> , "Overexpression of the atp-binding cassette half-transporter, abcg2 (mxr/bcrp/abcp1), in flavopiridol-resistnat human breast cancer cells," <i>Clinical Cancer Res.</i> , 7:145-152, 2001.
	C177	Rothenberg <i>et al.</i> , "Phase I and Pharmacokinetic Trial of Weekly CPT-11," <i>Journal of Clinical Oncology</i> , 11(11):2194-2204, 1993.
	C178	Rowinsky <i>et al.</i> , "Phase I and Pharmacological Study of the Novel Topoisomerase I Inhibitor 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) Administered as a Ninety-Minute Infusion Every 3 Weeks," <i>Cancer Research</i> , 54:427-436, 1994.
	C179	Rowinsky <i>et al.</i> , "Taxol: Pharmacology, Metabolism and Clinical Implications," <i>Cancer Surv.</i> , 17:283-304, 1993.
	C180	Rund <i>et al.</i> , "A mutation in the promoter of the multidrug resistance gene (mdr1) in human hematological malignancies may contribute to the patogenesis of resistant disease," <i>Adv. Exp Med Biol.</i> , 457:71-75, 1999.
SB	C181	Saeki <i>et al.</i> , "Human P-Glycoprotein Transports Cyclosporin A and FK506," <i>The Journal of Biological Chemistry</i> , 268(9):6077-6080, 1993.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006
--------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark J. Ratain <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C182	Sakata <i>et al.</i> , "Preventive Effect of TJ-14, a Kampo (Chinese herb) Medicine, on Diarrhea Induced by <u>Irinotecan</u> Hydrochloride (CPT-11)," <i>Gan-To-Kagaku-Ryoho</i> , 21(8):1241-4, July 1994; Abstract only.
	C183	Samuels <i>et al.</i> , "Modulation of vinblastine resistance with cyclosporine: A phase I study," <i>Clin. Pharmacol. Ther.</i> , 54:421-429, 1993.
	C184	Sausville <i>et al.</i> , "Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target," <i>Pharmacol Ther.</i> , 82:285-292, 1999.
	C185	Schinkel <i>et al.</i> , "Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs," <i>Cell</i> , 77(4):491-502, 1994.
	C186	Schrenk <i>et al.</i> , "Induction of multidrug resistance gene expression during cholestasis in rats and nonhuman primates," <i>Hepatol.</i> , 17:854-860, 1993.
	C187	Schrump <i>et al.</i> , "Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells," <i>Clin Cancer Res.</i> , 4:2885-2890, 1998.
	C188	Senderowicz <i>et al.</i> , "Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms," <i>J Clin Oncol.</i> , 16:2986-2999, 1998.
	C189	Shapiro <i>et al.</i> , "Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines," <i>Clin. Cancer Res.</i> , 5:2925-2938, 1999.
	C190	Sherr, "Cancer cell cycles," <i>Science</i> , 274:1672-1677, 1996.
	C191	Shirai <i>et al.</i> , "Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein," <i>Biochim. Biophys. Acta</i> , 1222(3):400-404, 1994.
	C192	Sinicrope <i>et al.</i> , "Modulation of P-glycoprotein-mediated transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles," <i>J. Biol. Chem.</i> , 267:24995-25002, 1992.
	C193	Slichenmyer <i>et al.</i> , "Camptothecin Analogues: Studies from The Johns Hopkins Oncology Center," <i>Cancer Chemother. Pharmacol.</i> , 34:S53-S57, 1994.
SB	C194	Slichenmyer <i>et al.</i> , "The Current Status of Camptothecin Analogues as Antitumor Agents," <i>Journal of the National Cancer Institute</i> , 85(4):271-291, February 1993.
SB	C195	Stadler <i>et al.</i> , "Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a university of chicago phase II consortium study," <i>J Clin Oncol.</i> , 18:371-375, 2000.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006
--------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark J. Ratain <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C196	Stinson <i>et al.</i> , "Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection," <i>Cancer Chemother. Pharmacol.</i> , 42(4):261-265, 1998.
	C197	Stocker, "Bilirubin is an antioxidant of possible physiological importance," <i>Science</i> , 235:1043-1046, 1987.
	C198	Strassburg <i>et al.</i> , "Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7," <i>J. Hepat.</i> , 34(6):865-872, 2001
	C199	Sugatani <i>et al.</i> , "Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia," <i>Biochem. Biophys. Res. Commun.</i> , 292(2):492-497, 2002.
	C200	Sugatani <i>et al.</i> , "The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR," <i>Hepatology</i> , 33(5):1232-1238, 2001.
	C201	Suzuki, "Antitumor drugs and potentiators aiming circumvention of drug resistance," <i>Jpn J Cancer Chemother</i> , 17:335-341, 1990.
	C202	Tamai and Safa, "Competitive interaction of cyclosporins with the vinca alkaloid-binding site of P-glycoprotein in multidrug resistant cells," <i>J. Biol. Chem.</i> , 265:16509-16513, 1990.
	C203	Taudou <i>et al.</i> , "Inhibition of DNA Synthesis and DNA Fragmentation in Stimulated Splenocytes by the Concerted Action of Topoisomerase I and II Poisons," <i>Biochem. Pharmacol.</i> , 45(2):331-337, 1993.
	C204	Thalhammer <i>et al.</i> , "Bile canalicular cationic dye secretion as a model for P-glycoprotein mediated transport," <i>Eur. J. Pharmacol.</i> , 270(2-3):213-220, 1994.
	C205	Thomas <i>et al.</i> , "Phase I clinical and pharmacokinetic trial of flavopiridol," <i>Proc Am Assoc Cancer Res</i> , 38:1496, Abstract #1496, 1997.
	C206	Toide <i>et al.</i> , "Hepatocyte nuclear factor 1 α is a causal factor responsible for interindividual differences in the expression of UDP-glucuronosyltransferase 2B7 mRNA in human livers," <i>Drug Metabolism and Disposition</i> , 30(6):613-615, 2002.
SB	C207	Trump <i>et al.</i> , "High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine," <i>J. Natl. Cancer Inst.</i> , 84(23):1811-1816, 1992.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006
--------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Mark J. Ratain <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C208	Tsuruo <i>et al.</i> , "Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors <i>in vitro</i> and <i>in vivo</i> ," <i>Cancer Chemother. Pharmacol.</i> , 21:71-74, 1988.
	C209	Tucker, "Clinical implications of genetic polymorphism in drug metabolism," <i>J. Pharm. Pharmacology</i> , 46:417-424, 1994.,
	C210	Vezmar and Georges, "Reversal of mfp-mediated doxorubicin resistance with quinoline-based drugs," <i>Biochem Pharmacol.</i> , 59:1245-1252, 2000.
	C211	Vore, "Canalicular transport: Discovery of ATP-dependent mechanisms," <i>Toxicol. Appl. Pharmacol.</i> , 118:2-7, 1993.
	C212	Wade <i>et al.</i> , "Variability in the pharmacokinetics of epirubicin: a population analysis," <i>Cancer Chemother. Pharmacol.</i> , 29:391-395, 1992.
	C213	Watanabe <i>et al.</i> , "Kinetic Analysis of Hepatobiliary Transport of Vincristine in Perfused," <i>Journal of Hepatology</i> , 16:77-88, 1992.
	C214	Wilson <i>et al.</i> , "A relationship between multidrug resistance and growth-state dependent cytotoxicity of the lysosomotropic detergent N-dodecylimidazole," <i>Biochem. Biophys. Res. Commun.</i> , 176(3):1377-1382, 1991.
	C215	Worland <i>et al.</i> , "Alteration of the phosphorylation state of p34 ^{cdc2} kinase by the flavone L86-8275 in breast carcinoma cells," <i>Biochem Pharmacol.</i> , 46:1831-1840, 1993.
	C216	Zacherl <i>et al.</i> , "Inhibition of P-Glycoprotein-Mediated Vinblastine Transport Across HCT-8 Intestinal Carcinoma Monolayers by Verapamil, Cyclosporine A and SDZ PSC 833 in Dependence on Extracellular pH," <i>Cancer Chemother. Pharmacol.</i> , 34:125-132, 1994.
SB	C217	Zhang <i>et al.</i> , "Inhibitory Effects of Homoharringtonine and Hydroxycamptothecin in Combination with Other Agents on Cancer Cell Growth," <i>Asia Pac. J. Pharmacol.</i> , 7:191-195, 1992.

25389367.1

EXAMINER: <i>/Sarae Bausch/</i>	DATE CONSIDERED: 07/24/2006
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	